Stock Scorecard



Stock Summary for Syndax Pharmaceuticals Inc (SNDX) - $15.95 as of 11/20/2024 8:43:21 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SNDX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SNDX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SNDX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SNDX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SNDX (36 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for SNDX

Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Revuforj® ( revumenib ) 11/20/2024 9:35:00 PM
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday - Roku ( NASDAQ:ROKU ) 11/18/2024 3:07:00 PM
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data 11/14/2024 7:16:00 PM
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - Syndax Pharmaceuticals ( NASDAQ:SNDX ) 11/12/2024 6:07:00 PM
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields - Johnson & Johnson ( NYSE:JNJ ) 11/6/2024 1:39:00 PM
Syndax Pharmaceuticals ( SNDX ) Reports Q3 Loss, Tops Revenue Estimates 11/5/2024 10:10:00 PM
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - Royalty Pharma ( NASDAQ:RPRX ) , Syndax Pharmaceuticals ( NASDAQ:SNDX ) 11/4/2024 9:15:00 PM
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales 10/29/2024 2:47:00 PM
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sempra ( NYSE:SRE ) 10/24/2024 11:40:00 AM
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know 10/22/2024 6:09:00 PM

Financial Details for SNDX

Company Overview

Ticker SNDX
Company Name Syndax Pharmaceuticals Inc
Country USA
Description Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 15.95
Price 4 Years Ago 22.24
Last Day Price Updated 11/20/2024 8:43:21 PM EST
Last Day Volume 1,261,777
Average Daily Volume 1,555,118
52-Week High 25.34
52-Week Low 15.03
Last Price to 52 Week Low 6.12%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 2.81
Free Cash Flow Ratio 3.50
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 6.99
Total Cash Per Share 4.56
Book Value Per Share Most Recent Quarter 4.28
Price to Book Ratio 3.69
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 84.45
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 85,358,000
Market Capitalization 1,361,460,100
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -40.19%
Reported EPS 12 Trailing Months -3.64
Reported EPS Past Year -2.63
Reported EPS Prior Year -2.96
Net Income Twelve Trailing Months -297,062,000
Net Income Past Year -209,360,000
Net Income Prior Year -149,338,000
Quarterly Revenue Growth YOY 33,297.00%
5-Year Revenue Growth 126.83%
Operating Margin Twelve Trailing Months -7.17

Balance Sheet

Total Cash Most Recent Quarter 389,607,000
Total Cash Past Year 570,698,000
Total Cash Prior Year 475,802,000
Net Cash Position Most Recent Quarter 329,401,000
Net Cash Position Past Year 510,803,336
Long Term Debt Past Year 59,894,664
Long Term Debt Prior Year 59,894,664
Total Debt Most Recent Quarter 60,206,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.86
Total Stockholder Equity Past Year 554,196,000
Total Stockholder Equity Prior Year 467,449,000
Total Stockholder Equity Most Recent Quarter 366,432,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -258,864,000
Free Cash Flow Per Share Twelve Trailing Months -3.03
Free Cash Flow Past Year -160,601,000
Free Cash Flow Prior Year -133,675,000

Options

Put/Call Ratio 0.27
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.28
MACD Signal 0.08
20-Day Bollinger Lower Band 16.49
20-Day Bollinger Middle Band 20.18
20-Day Bollinger Upper Band 23.86
Beta 0.92
RSI 37.92
50-Day SMA 20.86
150-Day SMA 20.24
200-Day SMA 19.92

System

Modified 11/19/2024 12:59:29 PM EST